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See Article, pages 515–521In the past decades, two effective strategies have been developed
to ﬁght against hepatitis B virus (HBV): neonatal vaccination to
prevent new infection and antiviral agents to treat existing
chronic hepatitis B. The immunogen in the hepatitis B vaccine is
derived from a recombinant HBV surface protein, which elicits
generation of a protective antibody directed against the HBV sur-
face antigen (anti-HBs). In Taiwan, following the launch of the
universal hepatitis B vaccination program, the carrier rate in the
vaccination era has signiﬁcantly decreased from around 10% to
nearly 1% [1]. Furthermore, the occurrence of hepatocellular car-
cinoma in children has decreased from 0.70 to 0.36 and further
down to <0.2 per 100,000, in 10 and 20 years following the cam-
paign [2]. Similar results have been observed in other parts of
the world [3]. On the other hand, oral antiviral agents functioning
as potent inhibitors of the HBV reverse transcriptase have proven
to be successful in suppressing HBV replication and thus halting
the progression of chronic liver diseases. Furthermore, pegylated
interferon therapy could lead to seroclearance of the HBV surface
antigen (HBsAg) in a small but substantial proportion of patients
and thus it could be considered a possible cure for the disease.
Despite the great improvements, several new challenges
emerge. HBV infection following completeness of neonatal vacci-
nation has been recognized in a signiﬁcant proportion of children.
Although most of these patients experience a silent and transient
infection with spontaneous recovery, some become chronic HBV
carriers. The post-vaccination HBV carriers present with several
different serological patterns. Serum HBsAg can be either positive
or negative, with or without co-existing anti-HBs [4,5]. As such,
the diagnosis of HBsAg-negative, post-vaccination HBV infection
can only be made by detection of positive serum HBV-DNA. The
latter condition is named ‘‘occult’’ HBV infection [6]. Previously,
detection of viremia in occult HBV infection was mostly con-
ducted by performing in-house PCR. Conceivably, signiﬁcant vari-
ations of sensitivity and speciﬁcity among different laboratories
are expected. PCRs targeted to at least two different regions of
the HBV genome are usually required to obtain convincing
results. With the availability of approved standardized qualitativeJournal of Hepatology 20
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The etiology of post-vaccination HBV infection is not com-
pletely understood. Incomplete blockade of mother-to-infant
transmission in high-titer maternal viremia appears to be an
important risk factor. In infants of HBsAg-positive mothers carry-
ing a high infectious risk, the post-vaccination HBsAg carrier rate
can be as high as 11% [7]. In infants born to HBV e antigen
(HBeAg)-positive mothers, the reported post-vaccination HBsAg
carrier rate ranged from 7.4% to 17.3% depending on different
types of vaccines, injection schedules, and ages of assessment.
In contrast, the overall post-vaccination HBsAg carrier rate,
regardless of maternal status, and completeness of vaccination,
is around or below 1%. The post-vaccination HBV viremia rate
has also been assessed by detection of serum HBV-DNA. The rate
ranges from 0% to 3.4% depending on reports from different coun-
tries [8–11]. In a limited number of studies, the rate of post-vac-
cination occult HBV infection has been assessed, ranging from 0%
to 10.9% [11–13]. In a study focusing on infants with HBsAg-posi-
tive carrier mothers, post-vaccination occult HBV infection was
detected in only 2% of patients [11]. In this issue of the Journal
of Hepatology, Shahmoradi et al. reported a surprisingly high
post-vaccination occult HBV infection rate (28%) in children with
HBsAg-positive mothers [14]. In this study, 75 children born to
HBsAg-positive mothers, previously immunized by HBIG and
given prophylactic vaccine, were assayed for HBV DNA followed
by direct sequencing. HBV DNA was detected in 21/75 (28%)
children. All were positive for anti-HBs, while only 5 (24%) were
positive for anti-HBc. Most notably, only 7 out of 75 mothers
(9.3%) were HBeAg-positive. This unusually high rate in Iranian
children suggests that besides risky contacts with highly infec-
tious mothers, other factors such as HBV genotype, racial differ-
ences, and nursing style may be involved. In Iran, genotype D is
the predominant genotype, which is different from most of the
other common genotypes in the world. Whether this factor con-
tributes to post-vaccination infection requires careful investiga-
tion. Delayed injection of HBIG >24 h after birth may also
contribute to the high infectious rate. In this study, the HBIG
was given within 72 h of birth. Another concern raised by this
report is that a high proportion of the infected children were
tested negative for serum antibody to the HBV core antigen
(anti-HBc), a marker generally used to determine whether the12 vol. 57 j 484–485
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patient has been infected by HBV. The present ﬁndings, if veriﬁed
further, question the reliability of this practice in post-vaccina-
tion HBV infection. One possible explanation for this unusual
observation is that the viremia was detected in an early stage
of infection when the anti-HBc level remained low. A longitudinal
follow-up with analysis of sequential serum samples can clarify
this issue. Alternatively, false positivity of HBV DNA results due
to contamination remains a concern.
A major virological issue in post-vaccination HBV infection is
the presence of the HBV S gene mutations in many of these
patients. The mutations usually develop on or around the ‘‘a’’
determinant, resulting in reduced binding ability to anti-HBs anti-
bodies. These ‘‘vaccine or immuneescape’’mutants can also lead to
detection failure of HBsAg thus resulting in a HBsAg-negative phe-
notype. Although this is a plausible scenario, a great proportion of
patients with post-vaccination occult HBV infection do not harbor
S genemutations on or around the ‘‘a’’ determinant, albeit remain-
ing HBsAg-negative. It is possible that other host or viral factors
leading to suppression of HBsAg secretion or productionmay con-
tribute to theHBsAgnegativity [15]. Alternatively, the viremiamay
be transient and thus the HBsAg level may be too low to be
detected especially in the presence of anti-HBs antibodies.
At this time, it is still unclear why some children cannot
develop sufﬁcient immunity against HBV post neonatal vaccina-
tion. Genetic variations and thus individual divergences in
immune responses should play a role. On the other hand, it
remains possible that post-vaccination infection can develop
despite sufﬁcient anti-HBs responses have been achieved. Some
vaccine escape mutants still replicate well under a relatively high
titer of anti-HBs. In view of that, it is always a viable question as
to whether the immune escape mutants can spread among indi-
viduals receiving complete vaccination. In antiviral therapies, S
gene mutants evolve in two ways. Firstly, the drug resistant
mutants carrying the polymerase gene mutations are accompa-
nied by the S gene mutations owing to the overlapping S and
polymerase reading frames. Secondly, following clearance of
HBV-DNA and HBsAg by potent antiviral therapies, anti-HBs
emerges followed by selection of the S gene mutants [16,17].
These vaccine-escape-like mutants with reduced HBs antigenicity
have been proposed to be a possible infectious source for post-
vaccination HBV infection [18]. At this time, however, only silent
and transient infection by drug resistant HBV mutants has been
experimentally demonstrated in vaccinated chimpanzees [19].
Identiﬁcation of the post-vaccination HBV infection is impor-
tant for the patients. Exacerbations of hepatitis activities have
been observed in clinical conditions such as usage of immuno-
suppressants and chemotherapeutic agents. This could be pre-
vented if occult HBV infection was recognized in advance. The
long-term consequences of chronic infection by the S gene
mutants are still unclear. However, increased oncogenicity has
been demonstrated in animal models for some S gene mutants
carrying stop codons [20]. Finally, the S gene mutations are usu-
ally accompanied by polymerase mutations. The effectiveness of
the current antiviral strategies in these mutants thus requires
further evaluation. Taken together, despite the progress made
in the war against HBV, we are now facing a new challenge,
where novel HBV mutants develop following effective vaccina-
tion and antiviral therapies. This could pose a health threat to
the general population. The epidemiology, transmission, long-
term consequence, and therapeutic strategy for these mutants
remain unknown and await further investigation.Journal of Hepatology 201Conﬂict of interest
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